KR102539877B1 - Gpr120 조정제로서 유용한 이환형 화합물 - Google Patents

Gpr120 조정제로서 유용한 이환형 화합물 Download PDF

Info

Publication number
KR102539877B1
KR102539877B1 KR1020197010276A KR20197010276A KR102539877B1 KR 102539877 B1 KR102539877 B1 KR 102539877B1 KR 1020197010276 A KR1020197010276 A KR 1020197010276A KR 20197010276 A KR20197010276 A KR 20197010276A KR 102539877 B1 KR102539877 B1 KR 102539877B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
membered
group
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197010276A
Other languages
English (en)
Korean (ko)
Other versions
KR20190068535A (ko
Inventor
브라이언 레이문도
엘레나 에스. 콜툰
존 그리핀
에릭 스탠젤란드
Original Assignee
인테그랄 헬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인테그랄 헬스 인코퍼레이티드 filed Critical 인테그랄 헬스 인코퍼레이티드
Publication of KR20190068535A publication Critical patent/KR20190068535A/ko
Application granted granted Critical
Publication of KR102539877B1 publication Critical patent/KR102539877B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197010276A 2016-09-12 2017-09-11 Gpr120 조정제로서 유용한 이환형 화합물 Active KR102539877B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393619P 2016-09-12 2016-09-12
US62/393,619 2016-09-12
PCT/US2017/050964 WO2018049328A1 (en) 2016-09-12 2017-09-11 Bicyclic compounds useful as gpr120 modulators

Publications (2)

Publication Number Publication Date
KR20190068535A KR20190068535A (ko) 2019-06-18
KR102539877B1 true KR102539877B1 (ko) 2023-06-05

Family

ID=61562078

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010276A Active KR102539877B1 (ko) 2016-09-12 2017-09-11 Gpr120 조정제로서 유용한 이환형 화합물

Country Status (6)

Country Link
US (2) US10865201B2 (enExample)
EP (1) EP3509588B1 (enExample)
JP (1) JP7065081B2 (enExample)
KR (1) KR102539877B1 (enExample)
CN (1) CN110121343B (enExample)
WO (1) WO2018049328A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2019202612A2 (en) * 2018-04-20 2019-10-24 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
CN111574414A (zh) * 2020-05-20 2020-08-25 上海毕得医药科技有限公司 一种4-溴-2-甲氧基苯磺酰氯的合成方法
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
CN114685395A (zh) * 2020-12-29 2022-07-01 浙江大学 一种2,3-二氢苯并[d]异噻唑类化合物及其应用
WO2024046323A1 (zh) * 2022-08-29 2024-03-07 山东大学 一种苯并五元氮环类化合物、其制备方法及医药用途
CN116730945B (zh) * 2023-08-10 2023-11-17 北京惠宇乐邦环保科技有限公司 糖精的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
WO2014096941A1 (en) * 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
DE3474547D1 (en) * 1983-12-02 1988-11-17 Shell Int Research Diphenyl ether herbicides
FR2659327A1 (fr) 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
DE69224115T2 (de) 1991-07-30 1998-08-20 Ciba Geigy Ag Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren
TW219935B (enExample) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
US6716836B2 (en) * 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
MY150746A (en) * 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
JP5175866B2 (ja) 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
KR101511396B1 (ko) 2007-07-20 2015-04-13 추가이 세이야쿠 가부시키가이샤 ｐ27 단백질 유도제
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
TW201200505A (en) * 2010-06-17 2012-01-01 Metabolex Inc GPR120 receptor agonists and uses thereof
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
AR088989A1 (es) 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
CA2887348A1 (en) 2012-10-11 2014-04-17 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
RU2015123982A (ru) 2012-12-03 2017-01-13 Ф. Хоффманн-Ля Рош Аг Соединения замещенных триазола и имидазола
CA2905729C (en) 2013-03-14 2021-11-09 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
EP2970157B1 (en) 2013-03-14 2018-04-25 Janssen Pharmaceutica NV Benzo-fused heterocyclic derivatives useful as agonists of gpr120
ES2784489T3 (es) 2013-06-27 2020-09-28 Lg Chemical Ltd Derivados de biarilo como agonistas de GPR120
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR100328A1 (es) 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
JP2017527559A (ja) 2014-08-29 2017-09-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
JP6486699B2 (ja) 2015-01-29 2019-03-20 国立大学法人金沢大学 脱水縮合剤
ES2989326T3 (es) * 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
CN110225752B (zh) * 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
WO2014096941A1 (en) * 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers

Also Published As

Publication number Publication date
EP3509588A1 (en) 2019-07-17
JP2019533642A (ja) 2019-11-21
JP7065081B2 (ja) 2022-05-11
EP3509588A4 (en) 2020-04-29
US20210347768A1 (en) 2021-11-11
WO2018049328A1 (en) 2018-03-15
US10865201B2 (en) 2020-12-15
CN110121343A (zh) 2019-08-13
KR20190068535A (ko) 2019-06-18
CN110121343B (zh) 2023-11-03
US20190218208A1 (en) 2019-07-18
US11919891B2 (en) 2024-03-05
CA3041038A1 (en) 2018-03-15
EP3509588B1 (en) 2023-06-07
EP3509588C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
KR102539877B1 (ko) Gpr120 조정제로서 유용한 이환형 화합물
KR102537985B1 (ko) Gpr120 조정제로서 유용한 단환형 화합물
JP6838796B2 (ja) メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
TWI444378B (zh) 具有β－分泌酶抑制作用之含硫雜環衍生物及其用途
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
US8940769B2 (en) Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
US20120172333A1 (en) Pyrrolo-pyridine derivatives as activators of ampk
JP2020515631A (ja) 縮合二環式化合物、その組成物及び応用
EP1003724B1 (de) Substituierte-chinolin-derivate mit antiviraler wirkung
KR20120101551A (ko) Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
TW202024020A (zh) 治療神經退化性疾病之方法
CA3041038C (en) Bicyclic compounds useful as gpr120 modulators
KR20160068948A (ko) RORyt의 이차 알코올 퀴놀리닐 조절제
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators
CA2927152C (en) Phenyl linked quinolinyl modulators of ror-gamma-t

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601